GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » ACME Laboratories Ltd (DHA:ACMELAB) » Definitions » Net Income From Continuing Operations

ACME Laboratories (DHA:ACMELAB) Net Income From Continuing Operations : BDT1,856 Mil (TTM As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is ACME Laboratories Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. ACME Laboratories's net income from continuing operations for the three months ended in Mar. 2024 was BDT582 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2024 was BDT1,856 Mil.

ACME Laboratories Net Income From Continuing Operations Historical Data

The historical data trend for ACME Laboratories's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ACME Laboratories Net Income From Continuing Operations Chart

ACME Laboratories Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Net Income From Continuing Operations
Get a 7-Day Free Trial 1,440.38 1,450.50 1,569.23 2,110.89 2,303.59

ACME Laboratories Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Mar24
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 532.85 536.29 614.65 658.57 582.30

ACME Laboratories Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT1,856 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ACME Laboratories (DHA:ACMELAB) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » ACME Laboratories Ltd (DHA:ACMELAB) » Definitions » Net Income From Continuing Operations
Comparable Companies
DHA:ORIONINFU DHA:AFCAGRO DHA:BEACONPHAR DHA:BXPHARMA ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692 NSE:DIVISLAB BOM:500124 VTRS NBIX SZSE:000963 SHSE:600085
Traded in Other Exchanges
N/A
Address
1/4, Kallayanpur, Mirpur Road, Court de la ACME, Dhaka, BGD, 1207
Website
https://www.acmeglobal.com
ACME Laboratories Ltd is engaged in the manufacturing, marketing, and distribution of generic pharmaceutical products in Bangladesh. The company offers pharmaceutical, ayurvedic, herbal, nutraceutical products, and veterinary products. It produces various forms of dosage including tablet, capsule, dry syrup, cream, ointment, powder and injection among others.

ACME Laboratories (DHA:ACMELAB) Headlines

No Headlines